Argos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in October
Argos Therapeutics, Inc. (NASDAQ:ARGS) saw a significant decrease in short interest during the month of October. As of October 13th, there was short interest totalling 2,706,234 shares, a decrease of 21.1% from the September 29th total of 3,429,642 shares. Based on an average trading volume of 5,538,609 shares, the short-interest ratio is presently 0.5 days. Currently, 8.9% of the company’s stock are sold short.
Argos Therapeutics (NASDAQ:ARGS) opened at 0.1587 on Friday. The firm’s 50-day moving average is $0.18 and its 200-day moving average is $0.31. The firm’s market cap is $8.72 million. Argos Therapeutics has a 52 week low of $0.15 and a 52 week high of $5.68.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%. On average, equities analysts anticipate that Argos Therapeutics will post ($1.19) earnings per share for the current year.
Separately, Zacks Investment Research cut shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $4.13.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.